Sinclair signs two separate deals with BMG

UK drugmaker Sinclair Pharma has signed two separate product and development deals with BMG Pharma, a privately-held US company. Under  the terms of the first agreement, Sinclair has out-licensed a range of  early-stage gynecology technologies to BMG in return for 3.5 million  euros ($4.4 million) that will be recognized as revenue. Separately,  Sinclair licensed a range of skin anti-infection products from BMG for  4.1 million euros. The range of creams, lotions, foams and cleansers  includes silver incorporated into nanospheres. The balance between the  two separate agreements of 600,000 euros is payable to BMG in  installments.